DEALS: Pfizer, Icagen ink development pact


Pfizer, Icagen ink development pact


DEALS

WHO

WITH

WHAT

SCOOP

Pfizer

Icagen

Development pact

Icagen stands to pocket up to $359 million in milestones for successful programs that target three sodium ion channels as a mechanism for controlling pain.

Sonic

Bioscientia

$256.4M buyout

Bioscientia has been acquired by Sonic Healthcare, which valued the company at €190 million.

Nektar Therapeutics

Bayer Healthcare

$225M licensing deal

Nektar Therapeutics is getting $50 million up front in a $175 million licensing deal for the successful development of a new therapy for severe pneumonia.

Archemix

Ophthotech

Licensing deal

Archemix granted Ophthotech worldwide rights to all ophthalmic uses of Archemix's proprietary aptamers targeting the C5 component of the complement cascade.

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.